

For brokers and producers only

Date: May 28, 2020

Market: All (except FEP and Medicare Supplement members)

2020 Rx Enhancements

Medical Pharmacy Management (MPM)

Effective **July 1, 2020**, the following 22 medications covered under the medical benefit will require prior authorization to better manage rising specialty drug costs. Prior authorization is required to ensure safe and effective use of these high-cost medications.

To view a full list of medications covered under the medical benefit that require prior authorization, visit the [Specialty Drug List](#). This list is updated monthly.

Drug Name	Drug Class	Drug Name	Drug Class
Adakveo	Sickle Cell	Jetrea	Retinal Disorders
Aliqopa	Oncology	Macugen	Retinal Disorders
Aranesp	Anemia	Mircera	Anemia
Beovu	Retinal Disorders	Polivy	Oncology
Duopa	Movement Disorders	Procrit	Anemia
Elzonris	Oncology	Reblozyl	Anemia
Epogen	Anemia	Retacrit	Anemia
Faslodex	Oncology	RiaSTAP	Hemophilia
Fibryga	Hemophilia	Takhzyro	Hereditary Angioedema
Firazyr	Hereditary Angioedema	Visudyne	Retinal Disorders
Haegarda	Hereditary Angioedema	Xiaflex	Dupuytren's Contracture

Failure to obtain prior authorization for these drugs may result in the denial of the claim payment. Impacted members were notified via letter in May and providers were notified in the April issue of [BlueLink](#).

For more information

Please contact Stephanie Holliday at stephanie.holiday@carefirst.com.